Deans' stroke musings: Admission monocyte-to-albumin ratio predicts 3-month functional outcomes after acute ischemic stroke: a retrospective cohort study

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, December 29, 2025

Admission monocyte-to-albumin ratio predicts 3-month functional outcomes after acute ischemic stroke: a retrospective cohort study

So what? YOU'RE PREDICTING FAILURE TO RECOVER! How does that help survivors? Are you that blitheringly stupid you think this does ANY GOOD AT ALL? Yes, I guess you are that stupid!

Admission monocyte-to-albumin ratio predicts 3-month functional outcomes after acute ischemic stroke: a retrospective cohort study

Weifeng Jiang³^*

¹Department of Neurology, The Quzhou Affiliated Hospital of Wenzhou Medical University (Quzhou People’s Hospital), Quzhou, Zhejiang, China
²Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
³Department of Gerontology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China

Background: The monocyte-to-albumin ratio (MAR) integrates systemic inflammation and nutritional status derived from routine laboratory data. We assessed whether the admission MAR is associated with 3-month functional outcomes following acute ischemic stroke (AIS).

Methods: We conducted a single-center, retrospective cohort study of consecutive adults with AIS admitted within 3 days of symptom onset (October 2023–March 2024). MAR was calculated from the admission monocyte counts and serum albumin levels. The primary outcome was poor 3-month functional status, defined as a modified Rankin Scale (mRS) score ≥3. Associations between MAR and outcomes were examined using multivariable logistic regression (with and without adjustment), smooth curve fitting, and prespecified subgroup analyses (sex, age, smoking status, drinking status, hypertension, diabetes status, eGFR, and TOAST subtype).

Results: Among 395 patients (mean age 66.2 years; 34.7% female), 59 (14.9%) had poor outcomes. A higher admission MAR independently predicted poor outcomes: per 1-unit increase, the adjusted odds ratio (OR) was 1.13 (95% CI 1.07–1.20; p < 0.001). Compared with the low tertile, patients with the high tertile had significantly greater odds (OR 3.21; 95% CI 1.25–8.20) with a linear trend (P for trend = 0.006). Smooth curve fitting demonstrated a largely monotonic increase in risk across the observed MAR range. Associations were consistent across subgroups with no significant interactions (all interactions p > 0.05). With respect to the TOAST subtype, the MAR remained significant for large-artery atherosclerosis (OR 1.10; 95% CI 1.02–1.20) and small-artery occlusion (OR 1.23; 95% CI 1.07–1.42), but not for cardioembolism.

Conclusion: The admission MAR is independently and positively associated with poor 3-month functional outcomes after AIS. MAR is a promising tool for early risk assessment when it is integrated with established predictors.